 |
97 Diseases |  |
239 Trials |
|
239 Trials |  |
14341 News |  |
| «12...7891011121314151617...166167» |
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk (clinicaltrials.gov) - Sep 28, 2023
P=N/A, N=645, Completed, Sponsor: Maatschap Cardiologie Zwolle
Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: May 2023 --> Sep 2023
- || rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
Biomarker, PK/PD data, Journal: Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy. (Pubmed Central) - Sep 28, 2023
of rivaroxaban of >137 pg/mL (5.94 OR, (95% CI, 3.13-12.99; p < 0.004)) and carriage of the T allelic variant polymorphism ABCB1 rs4148738 (8.97 OR (95% CI, 1.48-14.49; p < 0.017)), as well as for the BARC scale (5.76 OR (95% CI, 2.36-9.87; p < 0.018)). Measuring residual steady-state rivaroxaban concentrations and determining the carriage of the T allelic variant polymorphism ABCB1 rs4148738 may be applicable to high-risk patients for subsequent antithrombotic therapy modification.
- | Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
Trial completion date, Trial initiation date: THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) (clinicaltrials.gov) - Sep 28, 2023
P4, N=6660, Not yet recruiting, Sponsor: Imperial College London
Measuring residual steady-state rivaroxaban concentrations and determining the carriage of the T allelic variant polymorphism ABCB1 rs4148738 may be applicable to high-risk patients for subsequent antithrombotic therapy modification. Trial completion date: Aug 2026 --> Dec 2026 | Initiation date: Jun 2023 --> Oct 2023
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Clinical comprehensive evaluation of direct oral anticoagulants for patients with atrial fibrillation in China. (Pubmed Central) - Sep 27, 2023
The ranking of DOACs could help to support the decision-making in clinical practice. The framework could provide a reference for comprehensive evaluation of other drugs.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Observational data, Journal: Lower mortality with andexanet (Pubmed Central) - Sep 27, 2023
P=N/A
The framework could provide a reference for comprehensive evaluation of other drugs. In this large observational study, treatment with andexanet
- || rivaroxaban / Generic mfg.
PK/PD data, Journal: Effect of a High-Fat Diet on the Pharmacokinetics and Safety of Rivaroxaban in Healthy Chinese Subjects. (Pubmed Central) - Sep 23, 2023
The incidence of adverse events (AEs) was similar between the fasted and fed states, and no serious AEs were observed. Food significantly increased the exposure to rivaroxaban 10
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal: Adrenal hemorrhage and non-ST elevation myocardial infarction: an antiphospholipid syndrome dilemma. (Pubmed Central) - Sep 22, 2023
Non-ST elevation myocardial infarction, as well as new-onset left-sided adrenal hemorrhage, were diagnosed. The patient developed adrenal insufficiency; therefore, corticosteroids were administered, and warfarin was resumed to prevent further thrombotic episodes.
- || rivaroxaban / Generic mfg.
Observational data, Retrospective data, Review, Journal: Comparisons of Effectiveness and Safety between On-label Dosing, Off-label Underdosing and Off-label Overdosing in Asian and Non-Asian Atrial Fibrillation Patients Treated with Rivaroxaban: A Systematic Review and Meta-analysis of Observational Studies. (Pubmed Central) - Sep 22, 2023
Rivaroxaban dosing regimen following J-ROCKET criteria may serve as an alternative to ROCKET-AF criteria for the Asian population with NVAF, whereas the dosing regimen following ROCKET AF criteria was more favorable for the non-Asian population. Use of rivaroxaban 10mg despite of CrCl>50ml/min was associated with a higher risk of thromboembolism but a lower risk of major bleeding, while use of rivaroxaban 20mg despite of CrCl<50ml/min was associated with worse outcome in most clinical events.
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Journal: Who may benefit from low-dose Rivaroxaban plus Aspirin? Practical implications for outpatients with cardiovascular disease. (Pubmed Central) - Sep 22, 2023
Therefore, DPI is recommended in patients with CAD (+/- PAD) or symptomatic PAD at high ischaemic risk. The purpose of this review is to examine the clinical benefits and practical implications of DPI in CAD and PAD patients.
- | Bevyxxa (betrixaban) / AstraZeneca
Journal: An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis. (Pubmed Central) - Sep 20, 2023
Therefore, this article aims to explore the challenges faced during the approval process of betrixaban and provide a comprehensive review of the literature on its advantages and disadvantages as a long-term prophylaxis approach for VTE. Furthermore, we aim to identify the ambiguous points that require further investigation in future studies.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. (Pubmed Central) - Sep 20, 2023
Furthermore, we aim to identify the ambiguous points that require further investigation in future studies. In individuals with atrial fibrillation potentially eligible for DOAC therapy, the DOAC Score can help stratify patients on the basis of expected bleeding risk.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: A medication reconciliation failure: A case report and incident analysis. (Pubmed Central) - Sep 18, 2023
Anticoagulants are ranked first for the highest priority to receive a medication reconciliation. To achieve an optimal level of medication reconciliation, we ought to recognise and correct latent failures.
- | Savaysa (edoxaban) / Daiichi Sankyo
Reimbursement, Retrospective data, US reimbursement, Journal, Medicare: Utilization outcomes of direct oral anticoagulants in Medicare patients. (Pubmed Central) - Sep 18, 2023
To achieve an optimal level of medication reconciliation, we ought to recognise and correct latent failures. Medicare plans need to consider adherence, persistence, discontinuation and switching rates of DOACs to make the coverage decisions.
- | rivaroxaban / Generic mfg.
Journal: Platelets provide robustness of spatial blood coagulation to the variation of initial conditions. (Pubmed Central) - Sep 17, 2023
Inhibition of blood coagulation by natural endogenous inhibitor heparin was diminished in PRP, while the effect of the exogenous or artificial inhibitors (rivaroxaban, nitrophorin, hirudin) remained undisturbed in the presence of platelets...Coagulation factor deficiency greatly reduced amount of thrombin and decreased V in PFP rather than in PPR. Thus, platelets were redundant for clotting in normal plasma under physiological conditions but provided robustness of the coagulation system to the changes in initial conditions.
- ANALYSIS OF HIGH-RISK FACTORS AND CLINICAL FEATURES OF MAIN PULMONARY ARTERIAL THROMBOEMBOLISM (Convention Center Exhibit Hall) - Sep 15, 2023 - Abstract #CHEST2023CHEST_6265;
- LEFT VENTRICULAR NONCOMPACTION: A RARE CAUSE OF THROMBOEMBOLIC STROKE (Convention Center 323B) - Sep 15, 2023 - Abstract #CHEST2023CHEST_5953;
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal, Real-world evidence, Real-world: A Real-World Comparison of Apixaban and Rivaroxaban in Obese and Morbidly Obese Patients With Nonvalvular Atrial Fibrillation. (Pubmed Central) - Sep 15, 2023
Conclusion and Relevance: For obese and morbidly obese patients prescribed either apixaban or rivaroxaban for NVAF, rates of stroke, TIA, MI, and atrial thrombosis did not differ. The preferred DOAC for patients with class I-III obesity remains elusive, but current data points to a patient-centered approach for anticoagulant selection.
- || rivaroxaban / Generic mfg.
Enrollment closed, Enrollment change, Real-world evidence, Real-world: XARIN: A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF) (clinicaltrials.gov) - Sep 15, 2023
P=N/A, N=504, Active, not recruiting, Sponsor: Bayer
The preferred DOAC for patients with class I-III obesity remains elusive, but current data points to a patient-centered approach for anticoagulant selection. Recruiting --> Active, not recruiting | N=1000 --> 504
- || Savaysa (edoxaban) / Daiichi Sankyo, Bevyxxa (betrixaban) / AstraZeneca
Retrospective data, Review, Journal: An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis. (Pubmed Central) - Sep 13, 2023
However, no significant difference was observed in the incidence of gastrointestinal bleeding, major bleeding, thromboembolic events, and all-cause mortality. In addition, our network MA did not identify any specific DOAC treatment as more favorable than others.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs). (Pubmed Central) - Sep 13, 2023
In our single-center real-world experience, the choice of the DOAC for a patient with NVAF was tailored to specific clinical features and drug pharmacokinetics of the patient. As a result, a small number of adverse events were observed.
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date: ARIVA: Aspirin (clinicaltrials.gov) - Sep 13, 2023
P2, N=316, Suspended, Sponsor: University of Zurich
As a result, a small number of adverse events were observed. Trial completion date: Sep 2023 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Jul 2023 --> Dec 2023
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Enrollment closed: SIFNOS: A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France (clinicaltrials.gov) - Sep 13, 2023
P=N/A, N=1, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Sep 2023 --> Jun 2024 | Recruiting --> Suspended | Trial primary completion date: Jul 2023 --> Dec 2023 Not yet recruiting --> Active, not recruiting
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: Appropriateness of rivaroxaban and apixaban dosing in hospitalized patients with a newly diagnosed nonvalvular atrial fibrillation at a single tertiary hospital. (Pubmed Central) - Sep 12, 2023
The findings in our present study showed that majority of the patients received appropriate dosing of rivaroxaban and apixaban in hospitalized patients with NVAF. Healthcare providers should update themselves with the recent dosing recommendations for the non-vitamin K-antagonist oral anticoagulants in NVAF to further improve the dosing appropriateness in hospitalized patients with NVAF.
- | rivaroxaban / Generic mfg.
Biomarker, Journal: Acute pulmonary embolism presenting with electrocardiographic signs and serum biomarkers of ST-segment elevation myocardial infarction: a case report. (Pubmed Central) - Sep 11, 2023
Clinically, the ECG findings of ST-segment elevation and an upward T-wave in APE can be easily misdiagnosed as acute myocardial infarction. Physicians should maintain clinical suspicion through risk stratification to identify APE.
- | rivaroxaban / Generic mfg.
Journal: Safety and Efficacy of Cryoballoon Pulmonary Vein Isolation and Left Atrial Appendage Closure Combined Procedure and Half-Dose Rivaroxaban After Operation in Elderly Patients with Atrial Fibrillation. (Pubmed Central) - Sep 11, 2023
Besides, the two groups had no statistically significant difference in cerebral infarction/transient ischemic attack and device-related thrombosis (p > 0.05). This study suggests that cryo-balloon PVI and LAAC combined procedure and half-dose rivaroxaban after the operation is safe and effective in treating elderly patients with AF.
- || Review, Journal, Surgery: Pharmacological Thromboprophylaxis in People with Hemophilia Experiencing Orthopedic Surgery: What Does the Literature Say in 2023? (Pubmed Central) - Sep 9, 2023
However, the review of the literature on hemophiliac patients has shown that only a few authors have used pharmacological prophylaxis with LMWH (subcutaneous enoxaparin) for a short period of time (10-14 days) in some patients who had risk factors for VTE. Only one group of authors used a low dose of DOAC in the dusk after the surgical procedure and the next day, specifically in individuals at elevated risk of VTE and elevated risk of bleeding after the surgical procedure.
- | dabigatran etexilate / Generic mfg.
Journal: Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran. (Pubmed Central) - Sep 8, 2023
Switching eligible AF-patients from reduced-dose apixaban or rivaroxaban to lower-dose dabigatran has the potential to reduce healthcare payer's budget expenditures and provide health gains. Cost savings can potentially be further enhanced by market share adjustments and further price reductions.
- | rivaroxaban / Generic mfg.
Journal: Novel rivaroxaban-loaded microsphere systems with different surface microstructure for enhanced oral bioavailability. (Pubmed Central) - Sep 7, 2023
Finally, the solvent-evaporated microspheres showed the greatest improvement (solvent evaporating microspheres?>?solvent wetted microspheres?>?surface-attached microspheres???drug powder). Therefore, the solvent-evaporated microspheres may represent a novel oral dosage form that improves the oral bioavailability of rivaroxaban, a poorly soluble drug.
- | rivaroxaban / Generic mfg.
Preclinical, Journal: Effects of rivaroxaban on myocardial mitophagy in the rat heart. (Pubmed Central) - Sep 7, 2023
The present study provides an evidence that the mitophagy response is less in rivaroxaban-treated rats, showing the protective effect of rivaroxaban against acute ischemia. Rivaroxaban-treated rats may have reduced cell death in cardiomyocytes during myocardial infarction and thus have reduced damage to the heart tissue caused by myocardial infarction.
- | rivaroxaban / Generic mfg.
Journal: A 65-Year-Old Man with Bilateral Adrenal Hemorrhage Following Prophylaxis for Postoperative Deep Vein Thrombosis with Rivaroxaban. (Pubmed Central) - Sep 7, 2023
CONCLUSIONS This case supports previous cases of adrenal hemorrhage as a rare but serious association with rivaroxaban and highlights the importance of rapid diagnosis using imaging and monitoring of patients for this possible adverse effect. Practitioners must remain vigilant when prescribing anticoagulation therapy, especially in patients who are at an increased risk for adrenal hemorrhage.
- || rivaroxaban / Generic mfg., warfarin / Generic mfg.
Observational data, Review, Journal: Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies. (Pubmed Central) - Sep 7, 2023
Of the two studies reporting cost data, both were positive, showing lower costs for SSE for rivaroxaban versus warfarin and neutral cost for major bleeding costs. This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States.
- || rivaroxaban / Generic mfg.
PK/PD data, Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Coming full circle: The potential utility of real-world evidence to discern predictions from a physiologically based pharmacokinetic model. (Pubmed Central) - Sep 7, 2023
This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States. The odds ratio for DIB was 2.04 (CI 1.82, 2.3; p
- | rivaroxaban / Generic mfg., apixaban / Generic mfg.
Journal: ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. (Pubmed Central) - Sep 2, 2023
The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.
- || clopidogrel / Generic mfg.
Review, Journal: Clopidogrel as a Distinctive Cause of Insulin Autoimmune Syndrome: A Systematic Case Review. (Pubmed Central) - Aug 31, 2023
Glucocorticoids/immunotherapy might not be necessary for the long-term recovery of CIAS. To balance the risks of hypoglycemia and cardiovascular events, substituting clopidogrel with ticagrelor and rivaroxaban might be considered.
- || rivaroxaban / Generic mfg.
Clinical, Review, Journal: How to treat isolated distal deep vein thrombosis in 2023. (Pubmed Central) - Aug 31, 2023
In this review, we offer an updated overview on the epidemiology, risk factors, and clinical course of IDDVT, with a focus on the therapeutic management in light of current guideline recommendations and most recent evidence. We also present real-life clinical cases of IDDVT with proposed therapeutic approaches, and highlight major challenges and gaps in this field.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Observational data, Journal: Plasma Drug Values of DOACs in Patients Presenting with Gastrointestinal Bleeding: A Prospective Observational Study. (Pubmed Central) - Aug 30, 2023
Clinicians should be more judicious when prescribing dabigatran to the elderly and patients with renal failure. In these patients, dose adjustment, plasma drug monitoring, or substitution with other, more appropriate DOACs should be considered.
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Journal: Direct oral anticoagulants for deep vein thrombosis among patients with hereditary thrombophilia-A cohort study. (Pubmed Central) - Aug 30, 2023
Although statistically non-significant, symptoms' recurrence was also observed more frequently among patients under anti-Xa inhibitors than antithrombin inhibitors. This should be verified in larger comparative studies.
- Olumiant (baricitinib) / Incyte, Eli Lilly
Baricitinib: Therapeutic alternative in refractory livedoid vasculopathy. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_4084;
The most commonly used drugs include oral anticoagulants, systemic corticosteroids, intravenous immunoglobulins, and antiplatelet agents. We present a case of refractory livedoid vasculopathy with a positive response to oral baricitinib and review the existing literature regarding the pathophysiology of this condition, the most effective therapeutic options, and the potential role of JAK inhibitors in its management.
- rivaroxaban / Generic mfg., bisoprolol / Generic mfg., azathioprine / Generic mfg.
Allergic contact dermatitis to benzisothiazolinone in the laundry detergent (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2826;
We present a case of refractory livedoid vasculopathy with a positive response to oral baricitinib and review the existing literature regarding the pathophysiology of this condition, the most effective therapeutic options, and the potential role of JAK inhibitors in its management. There was initial suggestion of drug eruption such as rivaroxaban and bisoprolol which were started three weeks before the onset of rash...He could not tolerate azathioprine and declined further immunosuppressants...From our patient
- | rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
Journal: Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study. (Pubmed Central) - Aug 29, 2023
Apixaban had a lower bleeding risk than warfarin or rivaroxaban during initial treatment. During extended treatment, bleeding risk was similar for apixaban and rivaroxaban, and higher with warfarin.
- | rivaroxaban / Generic mfg.
Journal: Quality-by-Design-Based Development of Rivaroxaban-Loaded Liquisolid Compact Tablets with Improved Biopharmaceutical Attributes. (Pubmed Central) - Aug 28, 2023
The RXN LSC tablets showed longer bleeding times and higher rates of platelet aggregation than RXN API. Thus, RXN LSC tablets can be considered a facile, scalable technology.
- || rivaroxaban / Generic mfg., ticagrelor / Generic mfg., clopidogrel / Generic mfg.
Retrospective data, Review, Journal: Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Aug 28, 2023
However, it is important to note that this study is based on indirect comparisons, and there is currently a lack of direct evidence comparing various maintenance antiplatelet therapy regimens. Further high-quality studies are needed to address this gap and provide more conclusive evidence on the comparative effectiveness of different maintenance antiplatelet strategies.
- | rivaroxaban / Generic mfg.
Preclinical, Journal: In vivo evaluation of time-dependent antithrombotic effect of rivaroxaban-loaded poly(lactic-co-glycolic acid)/sodium lauryl sulfate or didodecyl dimethylammonium bromide nanoparticles in Wistar rats. (Pubmed Central) - Aug 28, 2023
Interestingly, the PNPs did not induce hemorrhagic events or cause liver enzyme alterations in vivo. These findings suggest that RVX-loaded SLS or DMAB PNPs are promising innovative therapeutic alternatives for the treatment of thromboembolic diseases.
- ||| rivaroxaban / Generic mfg.
Clinical, Clinical data, Journal, Adverse events: Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment. (Pubmed Central) - Aug 28, 2023
In conclusion, in patients with AF on rivaroxaban, the incidence of IS/TIA/SE/MI did not increase in those with renal impairment, suggesting that rivaroxaban may be an effective option in this subgroup. In patients with AF, male gender, heart failure, dependency, antiplatelets, CHADS-VASc, and HAS-BLED were associated with increased risk of adverse outcomes.
- | Journal, HEOR: The Budget Impact Analysis of Adopting Direct Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation Patients in Malawi. (Pubmed Central) - Aug 28, 2023
In patients with AF, male gender, heart failure, dependency, antiplatelets, CHADS-VASc, and HAS-BLED were associated with increased risk of adverse outcomes. With a fixed budget and current DOACs prices, Malawi can consider using DOACs in patients at the highest risk while waiting for cheaper generic versions.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan. (Pubmed Central) - Aug 27, 2023
Treatment with andexanet alfa rapidly reduced anti-FXa activity with favorable hemostatic efficacy in Japanese patients with acute major bleeding. Serious AEs of thrombotic events during rapid reversal of anti-FXa activity arose as particular safety concerns in this population as with previous studies.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal: Is the Pattern Changing? Atrial Fibrillation and Screening with Holter Electrocardiograms among Ischemic Stroke Patients in Greenland from 2016 to 2021. (Pubmed Central) - Aug 26, 2023
However, the insufficient use of Holter as a diagnostic tool may explain part of the drop, as well as improved preventive treatment with rivaroxaban among AF patients in Greenland. Regardless, IS remains common, and a focus on diagnostics and preventable risk factors should be maintained.
- || rosuvastatin / Generic mfg.
Clinical, Journal: The Effects of 3-Month Rosuvastatin Adjuvant Therapy on Post Thrombotic Syndrome following Deep Vein Thrombosis; a Randomized Clinical Trial. (Pubmed Central) - Aug 23, 2023
Rosuvastatin administration in combination with rivaroxaban or warfarin significantly reduces the level of inflammatory factors including CRP and D-dimer, compared to patients receiving anticoagulants alone. Rosuvastatin administration can significantly reduce the incidence of PTS and cause a difference in the size of the lower limbs within 3 months.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Rescue Sphenopalatine Ganglion Block for Treatment of PDPH in Anticoagulated Pediatric Patient (Exhibit Hall) - Aug 23, 2023 - Abstract #ASA2023ASA_5539;
A sphenopalatine ganglion block was performed instead, and the patient was switched to aspirin. Her symptoms persisted despite the block and an epidural blood patch was performed after the 72 hour wait period with resolution of symptoms.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
Intra-bronchial Factor Vii For Diffuse Alveolar Hemorrhage (South: Hall F) - Aug 23, 2023 - Abstract #ASA2023ASA_5122;
Patient received intra-bronchial Factor VII, and subsequent bronchoscopies did not show active bleeding. Despite resolution of hemorrhage, patient developed multiorgan failure and went into a ventricular arrhythmia resulting in death.